camelid
produc
convent
heterotetramer
antibodi
homodimer
heavychain
antibodi
antigenbind
region
homodimer
heavychain
antibodi
consist
one
singl
domain
call
vhh
vhh
provid
mani
advantag
convent
fullsiz
antibodi
current
use
antibodybas
fragment
fab
scfv
includ
high
specif
stabil
solubl
small
size
allow
recogn
unusu
antigen
site
deepli
penetr
tissu
sinc
discoveri
vhh
use
extens
diagnost
therapi
recent
decad
number
outbreak
diseas
transmiss
anim
human
rise
review
evalu
statu
vhh
diagnost
therapeut
biomolecular
agent
detect
treatment
zoonot
diseas
bacteri
parasit
viral
zoonosi
vhh
show
great
adapt
inhibit
neutral
pathogen
agent
creation
multifunct
vhhbase
diagnost
therapeut
molecul
zoonot
diseas
gener
monoclon
antibodi
mab
trigger
revolut
biotechnolog
therapeut
mab
belong
fastestgrow
branch
biotechnolog
howev
larg
size
molecul
may
hinder
effici
tissu
penetr
obstacl
overcom
use
fab
singlechain
fv
scfv
fragment
three
six
time
smaller
fullsiz
antibodi
howev
clone
fragment
consist
heavi
light
chain
variabl
region
link
disulfid
bridg
linker
challeng
alway
effici
express
altern
approach
avoid
pitfal
use
function
fragment
heavi
chain
antibodi
present
serum
anim
belong
camelida
famili
interact
antigen
virtu
one
singl
variabl
domain
refer
vhh
singledomain
antibodi
sdab
nanobodi
trademark
ablynx
combin
advantag
immunoglobulin
small
molecul
provid
altern
convent
antibodi
binder
deriv
altern
scaffold
shark
also
produc
uniqu
heavychain
immunoglobulin
associ
light
chain
refer
ignar
v
domain
ignar
often
appli
biotechnolog
biomed
field
review
camelida
famili
order
artiodactyla
consist
six
speci
dromedari
camelu
dromedariu
bactrian
camel
camelu
bactrianu
llama
lama
glama
guanaco
lama
guanico
alpaca
vicugna
paco
vicuna
vicugna
vicugna
anim
belong
famili
well
adapt
live
harsh
environ
desert
high
altitud
ungarwarom
et
al
azwai
et
al
isol
low
molecular
weight
iglik
protein
dromedari
serum
howev
detail
character
demonstr
potenti
use
protein
stem
work
hamer
laboratori
free
univers
brussel
author
demonstr
unusu
protein
heavychain
antibodi
hcab
devoid
light
chain
antibodi
form
homodim
interact
antigen
virtu
one
singl
variabl
domain
refer
vhh
vh
domain
heavychain
antibodi
distinguish
convent
vh
contrast
convent
antibodi
hcab
possess
domain
activ
antigenbind
fragment
heavi
chain
antibodi
clone
express
form
vhh
consist
one
domain
fig
percentag
hcab
bloodstream
camelid
vari
greatli
among
speci
reach
rel
high
level
camel
rang
wherea
maximum
level
south
american
camelid
speci
despit
absenc
light
chain
heavychain
antibodi
exhibit
broad
antigenbind
repertoir
exhibit
specif
characterist
substitut
three
four
hydrophob
residu
interact
vl
convent
antibodi
hydrophil
amino
acid
vh
possess
conserv
vhh
amino
acid
often
substitut
furthermor
complementar
determin
region
cdr
vhh
especi
statist
longer
convent
vhvl
antibodi
last
decad
vhh
receiv
progress
greater
interest
pharmaceut
biotechnolog
industri
due
specif
properti
inde
vhh
provid
follow
advantag
convent
antibodi
recombin
fragment
vhh
weakli
immunogen
human
gene
encod
share
high
sequenc
homolog
gene
belong
human
vh
famili
vhh
consist
one
domain
thu
easili
engin
clone
express
high
yield
use
variou
express
system
vhh
highli
solubl
stabl
even
denatur
condit
high
temperatur
high
variabl
length
sequenc
vhh
allow
recogn
varieti
protein
epitop
locat
surfac
protein
also
buri
deep
cleft
vhh
shown
recogn
wide
rang
epitop
type
small
hapten
bind
site
enzym
bind
epitop
recogn
convent
antibodi
small
size
basic
isolectr
point
vhh
allow
penetr
tissu
pass
barrier
bloodbrain
barrier
bind
intracellular
antigen
vhh
effici
function
wide
use
imag
explos
number
public
concern
applic
vhh
cover
use
pharmaceut
develop
biotechnolog
tool
mainli
focu
potenti
use
vhh
diagnosi
treatment
zoonot
diseas
zoonot
diseas
zd
infect
natur
spread
vertebr
anim
human
sever
recent
outbreak
ebola
zika
emphas
seriou
impact
diseas
human
health
expans
relat
global
trade
human
migrat
climat
chang
outbreak
contain
control
human
popul
affect
area
use
antibiot
develop
rapid
diagnost
test
howev
emerg
zd
still
major
challeng
crucial
need
new
tool
diagnosi
therapi
camelid
vhh
could
offer
attract
possibl
develop
tool
futur
campylobacteriosi
caus
mostli
campylobact
jejuni
campylobact
coli
poultri
natur
infect
without
clinic
sign
lead
caus
foodborn
gastroenter
human
worldwid
vhh
bind
c
jejuni
flagella
isol
riazi
et
al
engin
greater
thermal
proteolyt
stabil
hussack
et
al
obtain
highli
stabl
vhh
use
errorpron
polymeras
chain
reaction
disulfidebond
engin
vhh
direct
flagella
potent
inhibit
c
jejuni
motil
studi
prevent
signific
reduct
c
jejuni
colon
gastrointestin
tract
chicken
recent
vanmarsenil
et
al
describ
isol
character
vhh
multipl
campylobact
strain
vhh
bind
major
outer
membran
protein
momp
interact
c
jejuni
isol
c
coli
isol
could
potenti
use
therapi
diagnost
tool
escherichia
coli
facult
gramneg
bacterium
belong
famili
enterobacteriacea
although
normal
commens
natur
anim
mani
strain
food
waterborn
zoonot
pathogen
shiga
toxin
stx
produc
e
coli
stec
bacteria
includ
enterohemorrhag
e
coli
ehec
caus
discern
diseas
anim
reservoir
howev
diarrhea
hemorrhag
coliti
hemolyt
urem
syndrom
hu
common
human
major
virul
determin
stec
mainli
caus
shiga
toxin
vhh
neutral
andor
recent
obtain
vhh
specif
unabl
give
protect
lethal
dose
toxin
mice
trival
molecul
two
copi
vhh
one
copi
antialbumin
vhh
present
extend
halflif
abl
neutral
vivo
effect
toxin
mous
model
tremblay
et
al
show
vhh
heterodim
contain
two
link
neutral
vhh
gener
neutral
stx
much
effici
pool
individu
monom
moreov
coadministr
effector
ab
substanti
improv
abil
stx
toxinneutr
vhh
prevent
death
kidney
damag
mice
follow
challeng
listeriosi
bacteri
infect
caus
gramposit
bacterium
listeria
monocytogen
major
sourc
infect
contamin
food
diseas
primarili
affect
elderli
peopl
immunocompromis
patient
pregnant
women
caus
abort
newborn
vhh
specif
invasin
internalin
b
l
monocytogen
isol
inhibit
listeria
invas
vitro
crystal
structur
one
vhh
internalin
b
show
vhh
compet
cmet
target
cell
receptor
invasin
explain
protect
effect
two
vhh
specif
bind
three
l
monocytogen
serotyp
isol
nonimmun
librari
sandwich
elisa
develop
use
mab
antibodi
captur
one
vhh
detect
detect
limit
coloni
form
unit
cfu
ml
bacteria
milk
bacillu
anthraci
caus
organ
anthrax
sporeform
gramposit
bacillu
commonli
found
soil
endem
area
herbivor
infect
graze
recent
anthrax
detect
siberia
degrad
permafrost
due
global
warm
b
anthraci
also
one
import
biolog
warfar
agent
pathogen
natur
sporeform
capac
bioterrorist
event
unit
state
reveal
treatment
antibiot
alway
suffici
prevent
patient
death
due
effect
toxin
produc
bacteria
neutral
mab
may
therefor
great
therapeut
valu
complement
antibiot
treatment
prevent
toxindepend
symptom
anthrax
anthrax
caus
toxin
consist
protect
antigen
pa
lethal
factor
lf
edema
factor
ef
sever
vhh
direct
three
compon
toxin
shown
effici
anthrax
diseas
gene
therapi
adenovir
vector
express
bispecif
vhh
consist
two
link
vhh
target
differ
paneutr
epitop
test
mice
found
protect
anthrax
toxin
challeng
anthrax
spore
infect
taeniasi
occur
human
host
ingest
undercook
pork
infect
cysticerci
cysticercosi
caus
larval
stage
pork
tapeworm
taenia
solium
human
definit
host
harbor
adult
tapeworm
intestin
pig
human
infect
cysticerci
mab
obtain
thu
far
genusspecif
prevent
definit
diagnosi
infect
solium
inde
specif
binder
need
decker
et
al
isol
vhh
specif
glycoprotein
solium
cross
react
taenia
speci
sandwich
elisa
develop
serodiagnost
test
could
help
pig
epidemiolog
studi
monitor
efficaci
control
program
african
trypanosomiasi
sleep
sick
mainli
caus
unicellular
flagel
protozoan
parasit
trypanosoma
brucei
gambiens
belong
genu
trypanosoma
affect
mainli
remot
rural
area
distribut
coincid
mostli
habitat
hematophag
insect
vector
ie
tsets
fli
glossina
sp
multipl
vhh
alreadi
gener
parasit
review
trypanolyt
vhh
disturb
endocyt
machineri
parasit
flagellar
pocket
parasit
nontrypanolyt
vhh
made
potent
link
nontox
prodrug
cephalosporin
mustard
ccm
onto
highli
toxic
pdm
surfac
parasit
link
vhh
apolipoprotein
li
result
immunotoxin
lyse
almost
trypanosom
anoth
approach
coupl
pentamidin
firstlin
antitrypanosomiasi
vhh
effect
target
drug
parasit
vivo
tenfold
lower
dose
minim
full
cur
dose
free
pentamidin
incorpor
conjug
cure
infect
mice
whera
lower
dose
cure
parasit
develop
tsets
fli
subsequ
spread
parasit
control
express
trypanolyt
vhh
genet
modifi
tsets
fli
symbiont
addit
vhh
target
paraflagellar
rod
protein
varioiu
trypanosom
describ
mainli
use
diagnost
marker
trypanosiomasi
vhh
direct
congoles
aldolas
tcoald
develop
sandwich
immunoassay
vhh
highli
specif
recogn
trypanosom
brucei
brucei
vivax
evansi
influenza
virus
iav
member
rna
famili
orthomyxovirida
consist
subtyp
depend
variationcombin
surfac
glycoprotein
hemagglutinin
neuraminidas
iav
classifi
human
swine
siv
bat
equin
avian
influenza
virus
aiv
siv
aiv
transmit
pig
bird
human
respect
mostli
via
direct
contact
infect
anim
infect
human
rang
mild
selflimit
respiratorylik
ill
death
howev
pandem
outbreak
remain
unpredict
illustr
viru
also
name
mexican
flu
viru
occasion
zoonot
infect
virus
high
propens
reassort
siv
earmark
major
pandem
threat
sever
vhh
specif
influenza
virus
rais
nucleoprotein
ion
channel
protein
influenza
neuraminidas
hemaglutinin
vhh
neutral
influenza
virus
ploegh
et
al
exploit
abil
vhh
bind
intracellular
nucleoprotein
protein
block
viral
replic
lead
possibl
creat
new
therapeut
molecul
prevent
viral
escap
due
antigen
variat
altern
approach
creat
multival
vhh
increas
antivir
potenti
dimer
made
fusion
two
neutral
vhh
vhhfuse
immunoglobulin
fc
region
vitro
antivir
potenc
increas
log
rel
monomer
vhh
rabi
viru
rabv
belong
genu
lyssaviru
rna
famili
rhabdovirida
within
order
mononegaviral
despit
avail
vaccin
rabi
viru
rabv
rabi
continu
claim
human
live
per
year
mostli
develop
countri
asia
africa
vaccin
mostli
use
therapeut
postexposur
treatment
infect
combin
serious
bleed
injuri
recommend
complement
vaccin
local
instil
human
equin
rabi
immunoglobulin
rig
neutral
rabv
load
situ
current
critic
shortag
worldwid
explor
altern
approach
cocktail
human
human
neutral
mab
neutral
antirabv
vhh
direct
glycoprotein
rais
vhh
phage
librari
gener
immun
llama
inactiv
rabi
vaccin
genotyp
sanofi
pasteur
msd
ic
genotyp
strain
rang
nm
vhh
fuse
antialbumin
vhh
extend
serum
halflif
abl
neutral
viru
picomolar
dose
combin
treatment
base
vhh
vaccin
rabipur
novarti
act
synergist
protect
mice
intranas
rabi
infect
model
howev
princip
difficulti
antivir
approach
rabi
resid
specif
neurotrop
rabv
make
readili
access
access
cn
stage
molecul
capabl
cross
blood
brain
barrier
penetr
neuron
would
abl
inhibit
infect
footandmouth
diseas
fmd
contagi
viral
diseas
affect
cattl
swine
sheep
approxim
wildlif
speci
includ
llama
camel
potenti
rapid
spread
suscept
anim
diseas
identifi
worldwid
whereev
livestock
rais
last
year
massiv
outbreak
fmd
countri
formerli
free
diseas
unit
kingdom
taiwan
seven
antigen
distinct
serotyp
fmd
virus
identifi
c
asia
emerg
vaccin
use
effect
control
measur
fmd
outbreak
fmdfree
region
european
union
develop
novel
antivir
therapi
confer
rapid
protect
fmd
still
need
moreov
import
develop
rapid
diagnost
test
identif
variou
serotyp
virus
involv
fmd
outbreak
vhh
direct
serotyp
rais
provid
limit
protect
pig
trimer
consist
two
vhh
specif
fmdv
one
vhh
specif
porcin
ig
construct
increas
potenc
halflif
trimer
provid
better
protect
pig
delay
fmd
transmiss
specif
vhh
rais
fmd
asia
viru
also
obtain
use
develop
diagnost
assay
conjug
either
quantum
dot
carboxylmagnet
bead
review
provid
evid
possibl
use
vhh
valuabl
biomolecul
diagnosi
treatment
zd
includ
bacteri
parasit
viral
zoonosi
vhh
provid
mani
advantag
convent
antibodi
current
use
antibodi
base
fragment
eas
highlevel
product
small
size
high
stabil
make
vhh
extrem
reliabl
genet
chemic
modif
product
vhhbase
fusion
protein
increas
persist
vhh
serum
confer
addit
function
construct
multival
vhh
consist
two
link
vhh
target
variou
epitop
lead
increas
abil
neutral
toxin
virus
suggest
develop
approach
vhh
target
virus
yet
test
present
avail
antivir
therapeut
mab
variou
stage
preclin
evalu
mostli
target
surfac
antigen
often
divers
variabl
sequenc
eg
hiv
influenza
ha
effici
thu
requir
challeng
protein
engin
effort
obtain
antibodi
either
broadli
neutral
robust
viral
escap
antigen
variat
drift
altern
use
broadli
neutral
antibodi
bnab
antibodi
found
infect
mammal
abl
neutral
strain
given
highli
antigen
variabl
pathogen
bnab
isol
infect
human
hiv
influenza
dengu
virus
camelid
could
also
sourc
bnab
inde
antibodi
merscoronavirus
merscov
crimean
congo
hemorrhag
fever
viru
cchfv
rift
valley
fever
rfv
toxoplasma
gondii
rickettsia
sp
found
sera
infect
camel
wherea
antibodi
rabi
viru
vesicular
stomat
viru
fmd
viru
detect
llama
could
lead
possibl
isol
specif
broadli
neutral
vhh
mani
neutral
vhh
bind
differ
site
target
includ
hidden
antigen
site
isol
immun
infect
camelid
vhh
engin
variou
way
improv
diagnost
andor
therapeut
properti
efficaci
addit
vhh
readili
rapidli
penetr
tissu
even
brain
like
specif
vhhbase
construct
develop
neutral
agent
involv
brain
infect
influenza
zika
rabi
viru
overal
vhh
vhhbase
molecul
potenti
valuabl
diagnost
therapeut
reagent
treat
zd
